Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292).
JTO Clin Res Rep
March 2025
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Introduction: Selective RET inhibitors are approved for the treatment of RET-dependent cancers. A comprehensive characterization of mucocutaneous adverse events (MAEs) has not been performed; therefore, we characterized MAEs associated with the selective RET inhibitor, selpercatinib.
Methods: We assessed 133 patients with altered cancers treated with selpercatinib.
Chikungunya virus infection in the skin: histopathology and cutaneous immunological response.
Front Microbiol
January 2025
Laboratório das Interações Vírus-Hospedeiros, Instituto Oswaldo Cruz/Fundação Oswaldo Cruz (IOC/Fiocruz), Rio de Janeiro, Brazil.
virus (CHIKV) is an arbovirus, belonging to the family. The disease caused by CHIKV generally evolves with spontaneous resolution in a few weeks; however, progression to a chronic disease may occur. The most common symptoms are fever, myalgia, and arthralgia; however, skin manifestations may occur in 40 to 80% of infected individuals.
View Article and Find Full Text PDFTelitacicept for systemic lupus erythematosus with post‑surgical papillary thyroid carcinoma: A case report.
Biomed Rep
March 2025
Department of Rheumatology and Immunology, People's Hospital of Longhua, Shenzhen, Guangdong 518109, P.R. China.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a complex etiology primarily linked to abnormalities in B lymphocytes within the human body, resulting in the production of numerous pathogenic autoantibodies. Telitacicept is a relatively novel humanized, recombinant transmembrane activator, calcium modulator and cyclophilin ligand interactor fused with the Fc portion (TACI-Fc). It works by competitively inhibiting the TACI site, neutralizing the activity of B-cell lymphocyte stimulator and A proliferation-inducing ligand.
View Article and Find Full Text PDFPOEMS Syndrome.
Presse Med
March 2025
Department of Hematology and Cellular Therapy, National Reference Center "AL Amyloidosis and Other Monoclonal Immunoglobulin Deposit Diseases, University Hospital of Limoges, Limoges, France; CNRS UMR-7276, INSERM U1262, Team 3 BioPIC of CRIBL, University of Limoges, Limoges, France.
POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, Skin changes) is a syndrome that involves a monoclonal B-cell proliferation, most often plasmacytic, and a variable number of manifestations listed or not in the acronym. These manifestations include sclerotic bone lesions, plasmacytic Castleman disease, papillary edema, peripheral edema, ascites, thrombocytosis and/or polycythemia, venous and/or arterial thrombosis, and renal, pulmonary, and cardiac impairments . Diagnosis is often delayed due to the rarity of this entity and its clinical polymorphism, which can mimic other neurological disorders.
View Article and Find Full Text PDFLong-term observation of the in vivo safety of a new design of phakic refractive lens.
BMC Ophthalmol
January 2025
Fudan University Eye Ear Nose and Throat Hospital, Shanghai, China.
Background: To evaluate the biosafety, reduction in anterior capsule opacification, and fluctuation in intraocular pressure (IOP) of a new phakic refractive lens (PRL) with a sinusoidal drainage groove design.
Methods: This self-controlled experiment was performed on eight eyes of four rabbits. Each rabbit was implanted with a sinusoidal PRL (PRL-S5) in the right eye and a conventional posterior chamber PRL (PC-PRL) in the left eye.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!